Atty Docket No. 015280-317100US

PTO FAX NO.:

703-872-9306

ATTENTION:

Examiner Helms, Larry R.

TELEPHONE NO.:

571-272-0832

Group Art Unit 1642

RECEIVED
CENTRAL FAX CENTER

JUL 2 8 2004

OFFICIAL COMMUNICATION

FOR THE PERSONAL ATTENTION OF

OFFICIAL

EXAMINER Helms, Larry R.

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that the following document in re Application of FitzGerald et al., Application No. 09/381,497, filed February 17, 2000 for RECOMBINANT ANTIBODIES AND IMMUNOCONJUGATES TARGETED TO CD-22 BEARING CELLS AND TUMORS is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Document(s) Attached

1. Amendment Under 37 CFR 1.116 w/Appendix A

Number of pages being transmitted, including this page: 15

Dated: July 28, 2004

Malinda C. Dagit

PLEASE CONFIRM RECEIPT OF THIS PAPER BY RETURN FACSIMILE AT (415) 576-0300

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, Eighth Floor San Francisco, CA 94111-3834 Telephone: 415-576-0200

Fax: 415-576-0300

60271302 vI

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office, Fax No. 1-703-872-9306 on	EXPEDITED PROCEDURE – EXAMINING GROUP 1642
TOWNSEND and TOWNSEND and CREW LLP	PATENT Attorney Docket No.: 015280-317100US
By:	DHHS Ref. No.: E-059-1997/0-US-07

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED CENTRAL FAX CENTER

JUL 2 8 2004

In re application of:

FitzGerald et al.

Application No.: 09/381,497

Filed: February 17, 2000

For: RECOMBINANT ANTIBODIES AND IMMUNOCONJUGATES TARGETED TO CD-22 BEARING

CELLS AND TUMORS

Customer No.: 20350

Confirmation No. 4036

Helms, Larry R. Examiner:

Technology Center/Art Unit: 1642

AMENDMENT UNDER 37 CFR 1.116 EXPEDITED PROCEDURE EXAMINING

GROUP 1642

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In response to the Final Office Action mailed April 28, 2004, on the abovereferenced application, please enter the following amendment and remarks:

The Amendments to the Claims are reflect in the listing that begins on page 2 of

this paper.

The Remarks section begin on page 5 of this paper.